Cargando…

Exploring the Role of Antinuclear Antibody Positivity in the Diagnosis, Treatment, and Health Outcomes of Patients With Rheumatoid Arthritis

OBJECTIVE: The objective of this study was to describe differences in the clinical course of patients with rheumatoid arthritis (RA) who are antinuclear antibody (ANA)–positive compared with those who are ANA‐negative. METHODS: This was a retrospective population‐based cohort study of residents in O...

Descripción completa

Detalles Bibliográficos
Autores principales: Paknikar, Sujaytha S., Crowson, Cynthia S., Davis, John M., Thanarajasingam, Uma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207683/
https://www.ncbi.nlm.nih.gov/pubmed/34060254
http://dx.doi.org/10.1002/acr2.11271
_version_ 1783708819569770496
author Paknikar, Sujaytha S.
Crowson, Cynthia S.
Davis, John M.
Thanarajasingam, Uma
author_facet Paknikar, Sujaytha S.
Crowson, Cynthia S.
Davis, John M.
Thanarajasingam, Uma
author_sort Paknikar, Sujaytha S.
collection PubMed
description OBJECTIVE: The objective of this study was to describe differences in the clinical course of patients with rheumatoid arthritis (RA) who are antinuclear antibody (ANA)–positive compared with those who are ANA‐negative. METHODS: This was a retrospective population‐based cohort study of residents in Olmsted County, Minnesota, who first fulfilled 1987 American College of Rheumatology criteria for RA in 2009‐2014. Data were collected on first documentation of joint swelling. Data on rheumatoid factor or anti‐cyclic citrullinated peptide antibody testing and the ANA level were also collected. Comparisons between groups were performed by using χ(2) and rank sum tests. RESULTS: In this cohort, 64% of patients were tested for ANA within ±90 days of RA criteria fulfillment. In the161 patients with ANA testing, 25% were ANA‐positive. Patients who were ANA‐positive were younger, female, and less likely to be current smokers. ANA positivity did not differ between patients with RA who were seropositive and seronegative. In seropositive patients who were ANA‐positive, there was an increased time to fulfillment of RA criteria, increased time to treatment with disease‐modifying antirheumatic drugs (DMARDs), and increased likelihood of being treated with hydroxychloroquine as opposed to methotrexate. Other outcomes, including disease activity and mortality, did not differ significantly between groups. CONCLUSION: In patients with RA, important differences exist between those who are ANA‐positive and ANA‐negative in terms of time to fulfillment of RA criteria and time to DMARD initiation as well as choice of initial pharmacotherapy. These findings could indicate a difference in clinical presentation or perception of patients with RA who are ANA‐positive. Further research is needed to study the long‐term outcomes of patients with RA who are ANA‐positive.
format Online
Article
Text
id pubmed-8207683
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82076832021-06-25 Exploring the Role of Antinuclear Antibody Positivity in the Diagnosis, Treatment, and Health Outcomes of Patients With Rheumatoid Arthritis Paknikar, Sujaytha S. Crowson, Cynthia S. Davis, John M. Thanarajasingam, Uma ACR Open Rheumatol Original Articles OBJECTIVE: The objective of this study was to describe differences in the clinical course of patients with rheumatoid arthritis (RA) who are antinuclear antibody (ANA)–positive compared with those who are ANA‐negative. METHODS: This was a retrospective population‐based cohort study of residents in Olmsted County, Minnesota, who first fulfilled 1987 American College of Rheumatology criteria for RA in 2009‐2014. Data were collected on first documentation of joint swelling. Data on rheumatoid factor or anti‐cyclic citrullinated peptide antibody testing and the ANA level were also collected. Comparisons between groups were performed by using χ(2) and rank sum tests. RESULTS: In this cohort, 64% of patients were tested for ANA within ±90 days of RA criteria fulfillment. In the161 patients with ANA testing, 25% were ANA‐positive. Patients who were ANA‐positive were younger, female, and less likely to be current smokers. ANA positivity did not differ between patients with RA who were seropositive and seronegative. In seropositive patients who were ANA‐positive, there was an increased time to fulfillment of RA criteria, increased time to treatment with disease‐modifying antirheumatic drugs (DMARDs), and increased likelihood of being treated with hydroxychloroquine as opposed to methotrexate. Other outcomes, including disease activity and mortality, did not differ significantly between groups. CONCLUSION: In patients with RA, important differences exist between those who are ANA‐positive and ANA‐negative in terms of time to fulfillment of RA criteria and time to DMARD initiation as well as choice of initial pharmacotherapy. These findings could indicate a difference in clinical presentation or perception of patients with RA who are ANA‐positive. Further research is needed to study the long‐term outcomes of patients with RA who are ANA‐positive. John Wiley and Sons Inc. 2021-05-31 /pmc/articles/PMC8207683/ /pubmed/34060254 http://dx.doi.org/10.1002/acr2.11271 Text en © 2021 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Paknikar, Sujaytha S.
Crowson, Cynthia S.
Davis, John M.
Thanarajasingam, Uma
Exploring the Role of Antinuclear Antibody Positivity in the Diagnosis, Treatment, and Health Outcomes of Patients With Rheumatoid Arthritis
title Exploring the Role of Antinuclear Antibody Positivity in the Diagnosis, Treatment, and Health Outcomes of Patients With Rheumatoid Arthritis
title_full Exploring the Role of Antinuclear Antibody Positivity in the Diagnosis, Treatment, and Health Outcomes of Patients With Rheumatoid Arthritis
title_fullStr Exploring the Role of Antinuclear Antibody Positivity in the Diagnosis, Treatment, and Health Outcomes of Patients With Rheumatoid Arthritis
title_full_unstemmed Exploring the Role of Antinuclear Antibody Positivity in the Diagnosis, Treatment, and Health Outcomes of Patients With Rheumatoid Arthritis
title_short Exploring the Role of Antinuclear Antibody Positivity in the Diagnosis, Treatment, and Health Outcomes of Patients With Rheumatoid Arthritis
title_sort exploring the role of antinuclear antibody positivity in the diagnosis, treatment, and health outcomes of patients with rheumatoid arthritis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207683/
https://www.ncbi.nlm.nih.gov/pubmed/34060254
http://dx.doi.org/10.1002/acr2.11271
work_keys_str_mv AT paknikarsujaythas exploringtheroleofantinuclearantibodypositivityinthediagnosistreatmentandhealthoutcomesofpatientswithrheumatoidarthritis
AT crowsoncynthias exploringtheroleofantinuclearantibodypositivityinthediagnosistreatmentandhealthoutcomesofpatientswithrheumatoidarthritis
AT davisjohnm exploringtheroleofantinuclearantibodypositivityinthediagnosistreatmentandhealthoutcomesofpatientswithrheumatoidarthritis
AT thanarajasingamuma exploringtheroleofantinuclearantibodypositivityinthediagnosistreatmentandhealthoutcomesofpatientswithrheumatoidarthritis